Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Royalty Pharma plc    RPRX   GB00BMVP7Y09

ROYALTY PHARMA PLC

(RPRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2020 10/16/2020 10/19/2020 10/20/2020 10/21/2020 Date
42.48(c) 41.81(c) 40.27(c) 40.09(c) 38.34 Last
2 168 602 7 406 152 3 108 621 2 300 147 1 392 209 Volume
-0.72% -1.58% -3.68% -0.45% -4.37% Change
More quotes
Financials (USD)
Sales 2020 1 964 M - -
Net income 2020 1 420 M - -
Net Debt 2020 3 613 M - -
P/E ratio 2020 17,2x
Yield 2020 1,53%
Sales 2021 2 145 M - -
Net income 2021 1 631 M - -
Net Debt 2021 3 950 M - -
P/E ratio 2021 14,9x
Yield 2021 1,70%
Capitalization 14 735 M 14 735 M -
EV / Sales 2020 9,34x
EV / Sales 2021 8,71x
Nbr of Employees -
Free-Float 49,2%
More Financials
Company
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates. 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
All news about ROYALTY PHARMA PLC
04:33pRoyalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Sh..
GL
10/19Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 1..
GL
10/16ROYALTY PHARMA : Announces Pricing of Secondary Offering of Class A Shares by Se..
PU
10/15Royalty Pharma Announces Pricing of Secondary Offering of Class A Ordinary Sh..
GL
10/15Royalty Pharma Declares Fourth-Quarter 2020 Dividend
GL
10/15Morgan Stanley profit crushes estimates on trading strength
RE
10/13Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Sel..
GL
09/16Snowflake IPO raises $3.36 billion in year's biggest U.S. listing
RE
09/15ROYALTY PHARMA : Snowflake IPO raises $3.36 bln in year's biggest U.S. listing
RE
09/14Sequoia-backed Snowflake to raise $3.08 billion in biggest 2020 U.S. IPO
RE
09/02Royalty Pharma Declares Third-Quarter 2020 Dividend
GL
08/25Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes
GL
08/19Royalty Pharma Announces Launch of Senior Notes Offering
GL
08/12Royalty Pharma Reports Second Quarter 2020 Results
GL
08/07Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Mi..
GL
More news
News in other languages on ROYALTY PHARMA PLC
08/07ROYALTY PHARMA PLC : Veröffentlichung des Halbjahresergebnisses
08/07ROYALTY PHARMA PLC : publication des résultats semestriels
06/17EN DIRECT DES MARCHES : Kering, Capgemini, Ipsen, Bic, Cafom, Biosynex, Qualc..
06/17Miracle statistique et réveil du Covid
06/16AKTIE IM FOKUS : Börsengang von Royalty Pharma kommt bei Anlegern gut an
More news
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 51,83 $
Last Close Price 40,27 $
Spread / Highest target 39,1%
Spread / Average Target 28,7%
Spread / Lowest Target 16,7%
EPS Revisions
Managers
NameTitle
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
Errol B. de Souza Independent Director
William E. Ford Independent Director
Mario Germano Giuliani Director
Sector and Competitors
1st jan.Capitalization (M$)
ROYALTY PHARMA PLC0.00%14 735
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-3.14%210 050
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349